Two-year efficacy and safety data analyses from Phase III SUNSHINE and SUNRISE trials of continuous Cosentyx® (secukinumab) treatment in HS…
One poster will share pooled INTEGUMENT data of ZORYVE® (roflumilast) cream 0.15% in atopic dermatitis (AD) in patients with prior…
JENA, Germany, Feb. 28, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today…
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR…
Proposed study of Ampligen as a vaccine adjuvant to increase cross-reactivity to influenza strains Paul Goepfert, MD, Director for the…
Recommendation based on the findings from the Phase 3 QUASAR programme in ulcerative colitis1 Beerse, Belgium (28 February 2025) –…
Noom + HRTRx blends Noom’s proven behavior change program with HRT medication to achieve whole-person healthThe new offering builds on…
DUBLIN, Ireland, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human…
HALO™ Clarity Devices Successfully Shipped for First Phase of Clinical TrialsHOUSTON, TX, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology,…
CORE IR & PR to support strategic communications in conjunction with corporate development and commercial activities SCOTTSDALE, Ariz., Feb. 28,…